Literature DB >> 3197989

Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides?

J R Thornton1, H Dean, M S Losowsky.   

Abstract

Methionine enkephalin and catecholamines were measured in carefully collected plasma samples from 25 patients with cirrhosis and ascites, and 25 with cirrhosis without ascites, 15 disease and 15 healthy controls. Methionine enkephalin was invariably raised in the ascites group, the median value being 4.6-6.9 times that of the other three groups. Similarly, in the ascites group, median noradrenaline was increased 2.5-4.2 and median adrenaline 1.8-2.5 times that of the other groups. Plasma methionine enkephalin is considerably raised in patients with cirrhotic ascites and has actions which could enable it to be an initiating factor of ascites formation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3197989      PMCID: PMC1434349          DOI: 10.1136/gut.29.9.1167

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  50 in total

1.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

2.  Inhibition of neuroeffector transmission in the rabbit mesenteric artery by [Met5]enkephalin.

Authors:  P Illes; D Ramme; K Starke
Journal:  Eur J Pharmacol       Date:  1985-01-08       Impact factor: 4.432

3.  Met-enkephalin circulates in human plasma.

Authors:  V Clement-Jones; P J Lowry; L H Rees; G M Besser
Journal:  Nature       Date:  1980-01-17       Impact factor: 49.962

4.  The effect of epinephrine (USP), l-epinephrine, and l-norepinephrine on glomerular filtration rate, renal plasma flow, and the urinary excretion of sodium, potassium, and water in normal man.

Authors:  C M SMYTHE; J F NICKEL; S E BRADLEY
Journal:  J Clin Invest       Date:  1952-05       Impact factor: 14.808

5.  Endogenous opioid activity in clinical hemorrhagic shock.

Authors:  C H Shatney; R M Cohen; M R Cohen; D K Imagawa
Journal:  Surg Gynecol Obstet       Date:  1985-06

6.  Hemorrhagic hypotension increases plasma beta-endorphin concentrations in the nonhuman primate.

Authors:  B Chernow; C R Lake; S Teich; E H Mougey; J Meyerhoff; L C Casey; J R Fletcher
Journal:  Crit Care Med       Date:  1986-05       Impact factor: 7.598

7.  Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release.

Authors:  H Ring-Larsen; B Hesse; J H Henriksen; N J Christensen
Journal:  Hepatology       Date:  1982 May-Jun       Impact factor: 17.425

8.  Studies on circulating met-enkephalin and beta-endorphin: normal subjects and patients with renal and adrenal disease.

Authors:  R Smith; A Grossman; R Gaillard; V Clement-Jones; S Ratter; J Mallinson; P J Lowry; G M Besser; L H Rees
Journal:  Clin Endocrinol (Oxf)       Date:  1981-09       Impact factor: 3.478

9.  Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis.

Authors:  D G Bichet; V J Van Putten; R W Schrier
Journal:  N Engl J Med       Date:  1982-12-16       Impact factor: 91.245

10.  Histamine release induced by dynorphin-(1-13) from rat mast cells.

Authors:  K Sugiyama; H Furuta
Journal:  Jpn J Pharmacol       Date:  1984-07
View more
  11 in total

1.  Plasma beta endorphin in cirrhosis and renal failure.

Authors:  J R Thornton; M S Losowsky
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

2.  Plasma leucine enkephalin is increased in liver disease.

Authors:  J R Thornton; M S Losowsky
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

3.  Plasma methionine enkephalin concentration and prognosis in primary biliary cirrhosis.

Authors:  J R Thornton; M S Losowsky
Journal:  BMJ       Date:  1988-11-12

4.  Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia.

Authors:  J Charneau; R Petit; P Calès; A Dauver; J Boyer
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 5.  Aetiology and pathophysiology of chronic liver disorders.

Authors:  J Schölmerich; A Holstege
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Opioid peptides and primary biliary cirrhosis.

Authors:  J R Thornton; M S Losowsky
Journal:  BMJ       Date:  1988-12-10

Review 8.  Recent advances in the management of pruritus in chronic liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

9.  Further studies on aminopeptidase-M in blood in children with cholestatic liver diseases and viral hepatitis.

Authors:  R M Janas; J Socha; K Warnawin; J Rujner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

10.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.

Authors:  Shuhei Yoshikawa; Takeharu Asano; Mina Morino; Keita Matsumoto; Hitomi Kashima; Yudai Koito; Takaya Miura; Yuko Takahashi; Rumiko Tsuboi; Takehiro Ishii; Haruka Otake; Junichi Fujiwara; Masanari Sekine; Takeshi Uehara; Kazuhito Yuhashi; Satohiro Matsumoto; Shinichi Asabe; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.